Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Humans Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

NCT07527923
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis
Interventions
REGN20423, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • West Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Single and Multiple Ascending Dose Study of MT-501

NCT06762457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MT-501
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Intra-Arterial Microdosing: Proof-of-Concept in Humans

NCT02304211
View directory record Official record
Conditions
Healthy
Interventions
Insulin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

NCT02206711
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-955176
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers

NCT01006707
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Ondansetron
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

NCT01959945
View directory record Official record
Conditions
Influenza
Interventions
Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Auburn, Maine
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects

NCT01275157
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2452473
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

NCT00120081
View directory record Official record
Conditions
Hookworm Infection
Interventions
Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Temperature on Metabolism in Human Muscle

NCT00001753
View directory record Official record
Conditions
Healthy
Interventions
Magnetic resonance imaging
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

NCT04269031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

NCT02915302
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
1,950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

NCT03061981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Metformin, DA-1241
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Not yet recruiting Not applicable Interventional

Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection

NCT07859800
View directory record Official record
Conditions
Healthy Volunteer, Malaria
Interventions
18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
Diagnostic Test
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

NCT03143101
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
12
States / cities
Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 21, 2026, 5:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients

NCT01135875
View directory record Official record
Conditions
Glioblastoma Multiforme, Healthy Volunteers
Interventions
GBM Patients, Normal Controls
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects

NCT04819581
View directory record Official record
Conditions
Healthy
Interventions
SP-103, ZTlido
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

NCT00905762
View directory record Official record
Conditions
Healthy
Interventions
Gatifloxacin, Moxifloxacin, Besifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

NCT04945824
View directory record Official record
Conditions
Healthy
Interventions
Dexamethasone Ophthalmic, Dilator
Drug · Device
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of CAT-1004 Biomarkers in Healthy Subjects

NCT01670773
View directory record Official record
Conditions
Assessment of Mechanistic Blood Biomarkers in Healthy Humans
Interventions
CAT-1004, Salsalate + DHA, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 21, 2026, 5:52 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

NCT07225959
View directory record Official record
Conditions
Healthy Participants
Interventions
MK-1406 Injection
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 66 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Miami Lakes, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

NCT03510468
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

NCT05108818
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Mapping the Human HIV Chronobiome

NCT03133559
View directory record Official record
Conditions
Hiv, Healthy
Interventions
Observational
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 5:52 PM EDT